These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 9241011)
1. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Kopala LC; Good KP; Honer WG J Clin Psychopharmacol; 1997 Aug; 17(4):308-13. PubMed ID: 9241011 [TBL] [Abstract][Full Text] [Related]
2. Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. Zhong KX; Sweitzer DE; Hamer RM; Lieberman JA J Clin Psychiatry; 2006 Jul; 67(7):1093-103. PubMed ID: 16889453 [TBL] [Abstract][Full Text] [Related]
3. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670 [TBL] [Abstract][Full Text] [Related]
4. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. Honer WG; Kopala LC; Rabinowitz J J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group. Nair NP J Clin Psychopharmacol; 1998 Apr; 18(2):103-10. PubMed ID: 9555595 [TBL] [Abstract][Full Text] [Related]
6. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Heck AH; Haffmans PM; de Groot IW; Hoencamp E Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421 [TBL] [Abstract][Full Text] [Related]
7. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020 [TBL] [Abstract][Full Text] [Related]
9. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Anil Yağcioğlu AE; Kivircik Akdede BB; Turgut TI; Tümüklü M; Yazici MK; Alptekin K; Ertuğrul A; Jayathilake K; Göğüş A; Tunca Z; Meltzer HY J Clin Psychiatry; 2005 Jan; 66(1):63-72. PubMed ID: 15669890 [TBL] [Abstract][Full Text] [Related]
13. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Davidson M; Harvey PD; Vervarcke J; Gagiano CA; De Hooge JD; Bray G; Dose M; Barak Y; Haushofer M Int J Geriatr Psychiatry; 2000 Jun; 15(6):506-14. PubMed ID: 10861916 [TBL] [Abstract][Full Text] [Related]
14. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772 [TBL] [Abstract][Full Text] [Related]
15. A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. Huq ZU; J Clin Psychopharmacol; 2004 Apr; 24(2):220-4. PubMed ID: 15206670 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867 [TBL] [Abstract][Full Text] [Related]
17. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). Vieta E; Herraiz M; Fernández A; Gastó C; Benabarre A; Colom F; Martínez-Arán A; Reinares M J Clin Psychiatry; 2001 Aug; 62(8):623-30. PubMed ID: 11561935 [TBL] [Abstract][Full Text] [Related]
19. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
20. Risperidone in treatment-refractory schizophrenia. Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]